10 days ago
SNDX
AnalystsEtzer DaroutEtzer Darout's Stock Forecasts
AnalystsEtzer Darout
Sectors:
Analyst Ranking
Top 5%
#218 out of 5121 analysts
Average Return
+23.56%
Win Rate
50%67 out of 134
Risk vs Reward
Poor
Good
Etzer Darout's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Five Prime Therapeutics IncFPRX | +884.42% | $3.85 | $37.90 | 2020-09-22 - 2021-03-09 | Strong Buy |
Terns Pharmaceuticals IncTERN | +789.31% | $2.90 | $25.79 | 2025-05-13 - 2025-12-02 | Buy |
Scholar Rock Holding CorpSRRK | +278.17% | $8.45 | $31.96 | 2024-08-09 - 2025-08-08 | Buy |
C4 Therapeutics IncCCCC | +259.62% | $1.56 | $5.61 | 2023-11-03 - 2024-11-01 | Buy |
Scholar Rock Holding CorpSRRK | +253.34% | $9.43 | $33.32 | 2024-06-13 - 2025-06-12 | Buy |
Etzer Darout Analyst Color
Get additional color on Etzer Darout's coverage of popular stocks
10 days ago
KURA
10 days ago
IOVA
10 days ago
INCY
17 days ago
SRRK
a month ago
JANX
a month ago
KYMR
a month ago
XNCR
a month ago
RAPT
a month ago
CTMX
2 months ago
CCCC
3 months ago
IVA
8 months ago
VERV
Etzer Darout's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | 10 | Strong Buy | $36.00 | +39.59% | Maintains | 9 days ago |
Syndax Pharmaceuticals IncSNDX | 1 | Strong Buy | $35.00 | +86.27% | Maintains | 10 days ago |
Kura Oncology IncKURA | 1 | Strong Buy | $28.00 | +151.57% | Maintains | 10 days ago |
Iovance Biotherapeutics IncIOVA | 1 | Strong Buy | $9.00 | +320.56% | Maintains | 10 days ago |
Incyte CorpINCY | 1 | Strong Buy | $115.00 | +13.37% | Maintains | 10 days ago |
Scholar Rock Holding CorpSRRK | 7 | Strong Buy | $45.00 | +9.54% | Maintains | 17 days ago |
Celldex Therapeutics IncCLDX | 2 | Strong Sell | $21.00 | -21.26% | Maintains | 23 days ago |
Anaptysbio IncANAB | 2 | Strong Buy | $70.00 | +71.15% | Maintains | 23 days ago |
Rapt Therapeutics IncRAPT | 3 | Strong Buy | $56.00 | +98.02% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 4 | Strong Buy | $88.00 | +3.96% | Maintains | a month ago |
Janux Therapeutics IncJANX | 2 | Strong Buy | $48.00 | +202.65% | Maintains | a month ago |
Arvinas IncARVN | 6 | Strong Buy | $16.00 | +37.22% | Maintains | a month ago |
Kymera Therapeutics IncKYMR | 3 | Strong Buy | $70.00 | +8.92% | Maintains | a month ago |
Exelixis IncEXEL | 5 | Hold | $41.00 | -5.62% | Maintains | a month ago |
Xencor IncXNCR | 7 | Strong Buy | $23.00 | +43.84% | Upgrades | a month ago |
Summit Therapeutics IncSMMT | 2 | Strong Sell | $16.00 | -7.25% | Maintains | a month ago |
Cytomx Therapeutics IncCTMX | 10 | Strong Buy | $6.00 | +57.48% | Maintains | a month ago |
Tvardi Therapeutics IncTVRD | 1 | Strong Buy | $61.00 | +1,526.67% | Initiates Coverage On | 2 months ago |
Oruka Therapeutics IncORKA | 1 | Strong Buy | $48.00 | +72.48% | Initiates Coverage On | 2 months ago |
Monopar TherapeuticsMNPR | 1 | Strong Buy | $125.00 | +64.60% | Initiates Coverage On | 2 months ago |
Corvus Pharmaceuticals IncCRVS | 1 | Strong Buy | $16.00 | +98.76% | Initiates Coverage On | 2 months ago |
Abivax SaABVX | 1 | Strong Buy | $142.00 | +23.66% | Initiates Coverage On | 2 months ago |
Merus NvMRUS | 8 | Hold | $97.00 | +1.05% | Downgrades | 2 months ago |
C4 Therapeutics IncCCCC | 5 | Strong Buy | $10.00 | +311.52% | Maintains | 2 months ago |
Macrogenics IncMGNX | 9 | Strong Buy | $3.00 | +111.27% | Assumes | 3 months ago |
Inventiva SaIVA | 4 | Strong Buy | $13.00 | +211.00% | Maintains | 3 months ago |
Verve Therapeutics IncVERV | 1 | Strong Buy | $24.00 | +115.63% | Maintains | 8 months ago |
Biontech SeBNTX | 4 | Buy | $143.00 | +48.79% | Maintains | 9 months ago |
Q32 Bio IncQTTB | 3 | Hold | $3.00 | -12.02% | Downgrades | 10 months ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | +57.48% | Downgrades | a year ago |
Tourmaline Bio IncTRML | 1 | Buy | $50.00 | +4.21% | Initiates Coverage On | a year ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $35.00 | +114.07% | Initiates Coverage On | a year ago |
Jasper Therapeutics IncJSPR | 1 | Buy | $63.00 | +3,887.34% | Initiates Coverage On | a year ago |
Acrivon Therapeutics IncACRV | 7 | Buy | $27.00 | N/A | Maintains | a year ago |
Nuvalent IncNUVL | 6 | Buy | $134.00 | N/A | Maintains | a year ago |
Genmab AGMAB | 3 | Buy | $48.00 | N/A | Reiterates | a year ago |
Novartis AgNVS | 3 | Hold | $120.00 | N/A | Maintains | a year ago |
Y Mabs Therapeutics IncYMAB | 5 | Buy | $25.00 | N/A | Maintains | a year ago |
Fate Therapeutics IncFATE | 7 | Hold | $6.00 | N/A | Maintains | 2 years ago |
Astrazeneca PLCAZN | 4 | Buy | $82.00 | N/A | Maintains | 2 years ago |
Immunogen IncIMGN | 4 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Foghorn Therapeutics IncFHTX | 2 | Buy | $19.00 | N/A | Maintains | 3 years ago |
Seagen IncSGEN | 4 | Hold | $229.00 | N/A | Downgrades | 3 years ago |
Alnylam Pharmaceuticals IncALNY | 2 | Strong Buy | $170.00 | N/A | Upgrades | 4 years ago |
Traws Pharma IncTRAW | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 5 years ago |
Five Prime Therapeutics IncFPRX | 2 | Hold | $38.00 | N/A | Downgrades | 5 years ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $54.00 | N/A | Initiates Coverage On | 5 years ago |
Eidos Therapeutics IncEIDX | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Mirum Pharmaceuticals IncMIRM | 1 | Strong Buy | $38.00 | N/A | Maintains | 5 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $52.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.